Literature DB >> 18670641

Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora a kinase expression.

Xuesong Liu1, Yan Shi, Keith W Woods, Paul Hessler, Paul Kroeger, Julie Wilsbacher, Jieyi Wang, Jean Y Wang, Chunying Li, Qun Li, Saul H Rosenberg, Vincent L Giranda, Yan Luo.   

Abstract

Both Akt and Aurora A kinase have been shown to be important targets for intervention for cancer therapy. We report here that Compound A (A-443654), a specific Akt inhibitor, interferes with mitotic progression and bipolar spindle formation. Compound A induces G(2)/M accumulation, defects in centrosome separation, and formation of either monopolar arrays or disorganized spindles. On the basis of gene expression array studies, we identified Aurora A as one of the genes regulated transcriptionally by Akt inhibitors including Compound A. Inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, either by PI3K inhibitor LY294002 or by Compound A, dramatically inhibits the promoter activity of Aurora A, whereas the mammalian target of rapamycin inhibitor has little effect, suggesting that Akt might be responsible for up-regulating Aurora A for mitotic progression. Further analysis of the Aurora A promoter region indicates that the Ets element but not the Sp1 element is required for Compound A-sensitive transcriptional control of Aurora A. Overexpression of Aurora A in cells treated with Compound A attenuates the mitotic arrest and the defects in bipolar spindle formation induced by Akt inhibition. Our studies suggest that that Akt may promote mitotic progression through the transcriptional regulation of Aurora A.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18670641      PMCID: PMC2481570          DOI: 10.1593/neo.08408

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  48 in total

1.  Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase.

Authors:  Hui Yang; Teresa Burke; Jack Dempsey; Bruce Diaz; Elizabeth Collins; John Toth; Richard Beckmann; Xiang Ye
Journal:  FEBS Lett       Date:  2005-06-20       Impact factor: 4.124

Review 2.  Aurora kinases: shining lights on the therapeutic horizon?

Authors:  Paul D Andrews
Journal:  Oncogene       Date:  2005-07-28       Impact factor: 9.867

3.  Akt/protein kinase B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2/M transition.

Authors:  Kazuhiro Katayama; Naoya Fujita; Takashi Tsuruo
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

4.  Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells.

Authors:  Hua Yang; Lili He; Patricia Kruk; Santo V Nicosia; Jin Q Cheng
Journal:  Int J Cancer       Date:  2006-11-15       Impact factor: 7.396

5.  Chfr is required for tumor suppression and Aurora A regulation.

Authors:  Xiaochun Yu; Katherine Minter-Dykhouse; Liviu Malureanu; Wei-Meng Zhao; Dongwei Zhang; Carolin J Merkle; Irene M Ward; Hideyuki Saya; Guowei Fang; Jan van Deursen; Junjie Chen
Journal:  Nat Genet       Date:  2005-03-27       Impact factor: 38.330

6.  Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.

Authors:  Yan Luo; Alexander R Shoemaker; Xuesong Liu; Keith W Woods; Sheela A Thomas; Ron de Jong; Edward K Han; Tongmei Li; Vincent S Stoll; Jessica A Powlas; Anatol Oleksijew; Michael J Mitten; Yan Shi; Ran Guan; Thomas P McGonigal; Vered Klinghofer; Eric F Johnson; Joel D Leverson; Jennifer J Bouska; Mulugeta Mamo; Richard A Smith; Emily E Gramling-Evans; Bradley A Zinker; Amanda K Mika; Phong T Nguyen; Tilman Oltersdorf; Saul H Rosenberg; Qun Li; Vincent L Giranda
Journal:  Mol Cancer Ther       Date:  2005-06       Impact factor: 6.261

7.  Akt-induced promotion of cell-cycle progression at G2/M phase involves upregulation of NF-Y binding activity in PC12 cells.

Authors:  Sun-Ryung Lee; Jae-Han Park; Eui Kyun Park; Chin Ha Chung; Shin-Sung Kang; Ok-Sun Bang
Journal:  J Cell Physiol       Date:  2005-11       Impact factor: 6.384

8.  Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo.

Authors:  Yan Shi; Xuesong Liu; Edward K Han; Ran Guan; Alexander R Shoemaker; Anatol Oleksijew; Keith W Woods; John P Fisher; Vered Klinghofer; Loren Lasko; Thomas McGonigal; Qun Li; Saul H Rosenberg; Vincent L Giranda; Yan Luo
Journal:  Neoplasia       Date:  2005-11       Impact factor: 5.715

9.  Quantitative analysis of anti-apoptotic function of Akt in Akt1 and Akt2 double knock-out mouse embryonic fibroblast cells under normal and stressed conditions.

Authors:  Xuesong Liu; Yan Shi; Morris J Birnbaum; Keqiang Ye; Ron De Jong; Tillman Oltersdorf; Vincent L Giranda; Yan Luo
Journal:  J Biol Chem       Date:  2006-08-21       Impact factor: 5.157

10.  Aurora A, mitotic entry, and spindle bipolarity.

Authors:  Quentin Liu; Joan V Ruderman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-31       Impact factor: 11.205

View more
  18 in total

1.  INPP5E interacts with AURKA, linking phosphoinositide signaling to primary cilium stability.

Authors:  Olga V Plotnikova; Seongjin Seo; Denny L Cottle; Sarah Conduit; Sandra Hakim; Jennifer M Dyson; Christina A Mitchell; Ian M Smyth
Journal:  J Cell Sci       Date:  2014-11-13       Impact factor: 5.285

2.  Ubiquitin-specific cysteine protease 2a (USP2a) regulates the stability of Aurora-A.

Authors:  Yan Shi; Larry R Solomon; Ana Pereda-Lopez; Vincent L Giranda; Yan Luo; Eric F Johnson; Alexander R Shoemaker; Joel Leverson; Xuesong Liu
Journal:  J Biol Chem       Date:  2011-09-02       Impact factor: 5.157

3.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

4.  Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

Authors:  Paul M Barr; Hongli Li; Catherine Spier; Daruka Mahadevan; Michael LeBlanc; Mansoor Ul Haq; Bryan D Huber; Christopher R Flowers; Nina D Wagner-Johnston; Steven M Horwitz; Richard I Fisher; Bruce D Cheson; Sonali M Smith; Brad S Kahl; Nancy L Bartlett; Jonathan W Friedberg
Journal:  J Clin Oncol       Date:  2015-06-15       Impact factor: 44.544

5.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

6.  Growth inhibition and enhanced chemosensitivity induced by down-regulation of Aurora-A in human renal cell carcinoma Caki-2 cells using short hairpin RNA.

Authors:  Tomoaki Terakawa; Hideaki Miyake; Masafumi Kumano; Masato Fujisawa
Journal:  Oncol Lett       Date:  2011-04-28       Impact factor: 2.967

7.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

8.  Aurora-A expression is independently associated with chromosomal instability in colorectal cancer.

Authors:  Yoshifumi Baba; Katsuhiko Nosho; Kaori Shima; Natsumi Irahara; Shoko Kure; Saori Toyoda; Gregory J Kirkner; Ajay Goel; Charles S Fuchs; Shuji Ogino
Journal:  Neoplasia       Date:  2009-05       Impact factor: 5.715

9.  The PTEN-Akt pathway impacts the integrity and composition of mitotic centrosomes.

Authors:  Mary K Leonard; Natasha T Hill; Paula A Bubulya; Madhavi P Kadakia
Journal:  Cell Cycle       Date:  2013-04-09       Impact factor: 4.534

10.  Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival.

Authors:  Jin-E Yao; Min Yan; Zhong Guan; Chao-Bin Pan; Liang-Ping Xia; Chuan-Xing Li; Li-Hui Wang; Zi-Jie Long; Yan Zhao; Ming-Wei Li; Fei-Meng Zheng; Jie Xu; Dong-Jun Lin; Quentin Liu
Journal:  Mol Cancer       Date:  2009-11-05       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.